|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/55 | |||
| A61P 3/04 |
| (11) | Number of the document | 3402796 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17700748.1 |
| Date of filing the European patent application | 2017-01-09 | |
| (97) | Date of publication of the European application | 2018-11-21 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-18 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2017/050094 |
| Date | 2017-01-09 |
| (87) | Number | WO 2017/122116 |
| Date | 2017-07-20 |
| (30) | Number | Date | Country code |
| 201662279037 P | 2016-01-15 | US |
| (72) |
CHAPPIE, Thomas Allen, US
HENDERSON, Jaclyn Louise, US
YOUNG, Joseph Michael, US
WAGER, Travis T., US
KORMOS, Bethany Lyn, US
PATEL, Nandini Chaturbhai, US
SCIABOLA, Simone, US
TUTTLE, Jamison Bryce, US
VERHOEST, Patrick Robert, US
TUCKER, Joseph Walter, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS |
| 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS |